PE20160194A1 - Composiciones y metodos para tratar anemia - Google Patents

Composiciones y metodos para tratar anemia

Info

Publication number
PE20160194A1
PE20160194A1 PE2015002603A PE2015002603A PE20160194A1 PE 20160194 A1 PE20160194 A1 PE 20160194A1 PE 2015002603 A PE2015002603 A PE 2015002603A PE 2015002603 A PE2015002603 A PE 2015002603A PE 20160194 A1 PE20160194 A1 PE 20160194A1
Authority
PE
Peru
Prior art keywords
compositions
methods
alkyl
formula
pharmaceutically acceptable
Prior art date
Application number
PE2015002603A
Other languages
English (en)
Spanish (es)
Inventor
Akshay Buch
Joseph Gardner
Isaiah Shalwitz
John Janusz
Robert Shalwitz
Charlotte Hartman
Original Assignee
Akebia Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52022903&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20160194(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Akebia Therapeutics Inc filed Critical Akebia Therapeutics Inc
Publication of PE20160194A1 publication Critical patent/PE20160194A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pyridine Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PE2015002603A 2013-06-13 2014-06-04 Composiciones y metodos para tratar anemia PE20160194A1 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361834808P 2013-06-13 2013-06-13
US201361889478P 2013-10-10 2013-10-10
US201361898885P 2013-11-01 2013-11-01
US201361898890P 2013-11-01 2013-11-01
US201361912185P 2013-12-05 2013-12-05

Publications (1)

Publication Number Publication Date
PE20160194A1 true PE20160194A1 (es) 2016-04-20

Family

ID=52022903

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2015002603A PE20160194A1 (es) 2013-06-13 2014-06-04 Composiciones y metodos para tratar anemia
PE2020000452A PE20201496A1 (es) 2013-06-13 2014-06-04 Composiciones y metodos para tratar anemia

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2020000452A PE20201496A1 (es) 2013-06-13 2014-06-04 Composiciones y metodos para tratar anemia

Country Status (37)

Country Link
US (2) US11857543B2 (cg-RX-API-DMAC7.html)
EP (2) EP3007695B1 (cg-RX-API-DMAC7.html)
JP (6) JP2016521747A (cg-RX-API-DMAC7.html)
KR (4) KR20240055172A (cg-RX-API-DMAC7.html)
CN (3) CN114404414A (cg-RX-API-DMAC7.html)
AU (4) AU2014278543B2 (cg-RX-API-DMAC7.html)
BR (1) BR112015031027A2 (cg-RX-API-DMAC7.html)
CA (2) CA2914662C (cg-RX-API-DMAC7.html)
CL (2) CL2015003602A1 (cg-RX-API-DMAC7.html)
CY (2) CY1126699T1 (cg-RX-API-DMAC7.html)
DK (1) DK3007695T3 (cg-RX-API-DMAC7.html)
DO (1) DOP2015000297A (cg-RX-API-DMAC7.html)
EC (1) ECSP20058592A (cg-RX-API-DMAC7.html)
ES (1) ES2974273T3 (cg-RX-API-DMAC7.html)
FI (2) FI3007695T3 (cg-RX-API-DMAC7.html)
FR (1) FR24C1025I2 (cg-RX-API-DMAC7.html)
HR (1) HRP20240319T1 (cg-RX-API-DMAC7.html)
HU (2) HUE066123T2 (cg-RX-API-DMAC7.html)
IL (3) IL243047B (cg-RX-API-DMAC7.html)
LT (2) LT3007695T (cg-RX-API-DMAC7.html)
MX (3) MX391198B (cg-RX-API-DMAC7.html)
MY (1) MY204336A (cg-RX-API-DMAC7.html)
NL (1) NL301278I2 (cg-RX-API-DMAC7.html)
NO (1) NO2024025I1 (cg-RX-API-DMAC7.html)
NZ (3) NZ753904A (cg-RX-API-DMAC7.html)
PE (2) PE20160194A1 (cg-RX-API-DMAC7.html)
PH (2) PH12015502738B1 (cg-RX-API-DMAC7.html)
PL (1) PL3007695T3 (cg-RX-API-DMAC7.html)
PT (1) PT3007695T (cg-RX-API-DMAC7.html)
RS (1) RS65341B1 (cg-RX-API-DMAC7.html)
RU (2) RU2019134558A (cg-RX-API-DMAC7.html)
SG (2) SG10201910773VA (cg-RX-API-DMAC7.html)
SI (1) SI3007695T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202400092T1 (cg-RX-API-DMAC7.html)
TW (5) TWI856464B (cg-RX-API-DMAC7.html)
WO (1) WO2014200773A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA201509024B (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2009000286A (es) 2006-06-26 2009-03-20 Procter & Gamble Inhibidores de prolil hidroxilasa y metodos de uso.
NO2686520T3 (cg-RX-API-DMAC7.html) 2011-06-06 2018-03-17
EP2986207B1 (en) 2013-04-16 2024-03-20 Koninklijke Philips N.V. System and method for biventricular pacemaker pulse detection in surface ecg
PT3007695T (pt) * 2013-06-13 2024-03-07 Akebia Therapeutics Inc Composições e métodos para tratamento de anemia
AR099354A1 (es) 2013-11-15 2016-07-20 Akebia Therapeutics Inc Formas sólidas de ácido {[5-(3-clorofenil)-3-hidroxipiridin-2-carbonil]amino}acético, composiciones, y sus usos
CN107427503A (zh) 2015-01-23 2017-12-01 阿克比治疗有限公司 2‑(5‑(3‑氟苯基)‑3‑羟基吡啶甲酰胺)乙酸的固体形式、其组合物及用途
CR20170450A (es) * 2015-04-01 2018-04-03 Akebia Therapeutics Inc Composiciones y métodos para el tratamiento de la anemia
WO2018103600A1 (zh) * 2016-12-06 2018-06-14 深圳市塔吉瑞生物医药有限公司 一种取代的杂芳基酰胺化合物及包含该化合物的组合物及其用途
WO2019028150A1 (en) 2017-08-01 2019-02-07 Akebia Therapeutics, Inc. COMPOSITIONS FOR USE IN METHODS OF TREATING HEMOGLOBINOPATHIES
US11713298B2 (en) 2018-05-09 2023-08-01 Akebia Therapeutics, Inc. Process for preparing 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetic acid
JP2023501221A (ja) * 2019-10-31 2023-01-18 アケビア セラピューティクス インコーポレイテッド バダデュスタットを使用する治療方法
US11524939B2 (en) 2019-11-13 2022-12-13 Akebia Therapeutics, Inc. Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid
WO2021186356A1 (en) * 2020-03-17 2021-09-23 Cadila Healthcare Limited Formulation comprising hif prolyl hydroxylase inhibitors
US20210353612A1 (en) * 2020-04-29 2021-11-18 BioAge Labs, Inc. Hypoxia-inducible factor prolyl hydroxylase inhibitors for treating aging-related conditions
EP4181873A1 (en) 2020-06-19 2023-05-24 Akebia Therapeutics Inc. Modulation of drug-drug interactions of vadadustat
WO2022150623A1 (en) 2021-01-08 2022-07-14 Akebia Therapeutics, Inc. Compounds and composition for the treatment of anemia
AU2022206302A1 (en) 2021-01-08 2023-08-17 Akebia Therapeutics, Inc. Therapeutic methods using vadadustat
JP2024510926A (ja) 2021-03-01 2024-03-12 アケビア セラピューティクス インコーポレイテッド バダデュスタットの薬物間相互作用の調節

Family Cites Families (127)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3655679A (en) 1969-06-25 1972-04-11 Merck & Co Inc Certain aryl pyridine carboxylic acid derivatives
US3703582A (en) 1970-04-20 1972-11-21 Merck & Co Inc Aryl pyridine carboxylic acids in the treatment of inflammation
US3894920A (en) 1971-12-21 1975-07-15 Sagami Chem Res Process for preparing alkyl-substituted 3,6-dihydro-o-dioxin derivatives
US4016287A (en) 1972-07-17 1977-04-05 Boehringer Ingelheim Gmbh Dermatological compositions containing an acylamino-carboxylic acid or an alkyl ester thereof
CA1261335A (en) 1984-08-29 1989-09-26 Hoffmann-La Roche Limited/Hoffmann-La Roche Limitee Ethylenediamine monoamide derivatives
CN1023479C (zh) 1985-09-27 1994-01-12 弗·哈夫曼-拉罗切有限公司 乙二胺的单酰胺衍生物的制备方法
TW219933B (cg-RX-API-DMAC7.html) 1990-02-26 1994-02-01 Lilly Co Eli
US5405613A (en) 1991-12-11 1995-04-11 Creative Nutrition Canada Corp. Vitamin/mineral composition
TW352384B (en) 1992-03-24 1999-02-11 Hoechst Ag Sulfonamido- or sulfonamidocarbonylpyridine-2-carboxamides, process for their preparation and their use as pharmaceuticals
DE4219158A1 (de) 1992-06-11 1993-12-16 Thomae Gmbh Dr K Biphenylderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
EP0650961B1 (de) 1993-11-02 1997-03-05 Hoechst Aktiengesellschaft Substituierte heterocyclische Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
DE59401923D1 (de) 1993-11-02 1997-04-10 Hoechst Ag Substituierte heterocyclische Carbonsäureamidester, ihre Herstellung und ihre Verwendung als Arzneimittel
TW406076B (en) 1993-12-30 2000-09-21 Hoechst Ag Substituted heterocyclic carboxamides, their preparation and their use as pharmaceuticals
DE4410423A1 (de) 1994-03-25 1995-09-28 Hoechst Ag Sulfonamidocarbonylpyridin-2-carbonsäureamide sowie ihre Pyridin-N-oxide, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE4410480A1 (de) 1994-03-25 1995-09-28 Hoechst Ag Sulfonamidocarbonylpyridin-2-carbonsäureesteramide sowie ihre Pyridin-N-oxide, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US5789426A (en) 1995-01-20 1998-08-04 Cornell Research Foundation, Inc. Method for the treatment of fibroproliferative disorders by application of inhibitors of protein hydroxylation
DE19535571A1 (de) 1995-09-14 1997-03-20 Boehringer Mannheim Gmbh Pharmazeutische Kombinationspräparate und deren Verwendung zur Behandlung von Hämodialysepatienten
IL135495A (en) 1995-09-28 2002-12-01 Hoechst Ag Intermediate compounds for the preparation of quinoline-converted amines - 2 - carboxylic acid
JPH09221476A (ja) 1995-12-15 1997-08-26 Otsuka Pharmaceut Co Ltd 医薬組成物
WO1997041103A1 (de) 1996-04-30 1997-11-06 Hoechst Aktiengesellschaft 3-alkoxypyridin-2-carbonsäureamidester, ihre herstellung und ihre verwendung als arzneimittel
DE19620041A1 (de) 1996-05-17 1998-01-29 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten
DE19650215A1 (de) 1996-12-04 1998-06-10 Hoechst Ag 3-Hydroxypyridin-2-carbonsäureamidester, ihre Herstellung und ihre Verwendung als Arzneimittel
EP1024134A4 (en) 1997-10-09 2003-05-14 Ono Pharmaceutical Co DERIVATIVES OF AMINOBUTANIC ACID
DE19746287A1 (de) 1997-10-20 1999-04-22 Hoechst Marion Roussel De Gmbh Substituierte Isochinolin-2-Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
JP4495339B2 (ja) 1998-03-23 2010-07-07 アベンティス・ファーマスーティカルズ・インコーポレイテツド ピペリジニルおよびｎ−アミジノピペリジニル誘導体
GB9809213D0 (en) 1998-04-29 1998-07-01 Glaxo Group Ltd Pharmaceutical compositions
KR100724016B1 (ko) 1998-06-11 2007-05-31 파마시아 앤드 업존 캄파니 엘엘씨 델라비르딘 정제 제제
US6159379A (en) 1999-05-04 2000-12-12 Baker Hughes Incorporated Organic ammonium salts for the removal of water soluble organics in produced water
JP2001048786A (ja) 1999-08-05 2001-02-20 Yamanouchi Pharmaceut Co Ltd 三環式ヘテロアリール誘導体
US6589758B1 (en) 2000-05-19 2003-07-08 Amgen Inc. Crystal of a kinase-ligand complex and methods of use
EP1349531A1 (en) 2001-01-12 2003-10-08 Sun Pharmaceuticals Industries Ltd. Spaced drug delivery system
US6849718B2 (en) 2001-03-20 2005-02-01 Dana Farber Cancer Institute, Inc. Muteins of hypoxia inducible factor alpha and methods of use thereof
US6855510B2 (en) 2001-03-20 2005-02-15 Dana Farber Cancer Institute, Inc. Pharmaceuticals and methods for treating hypoxia and screening methods therefor
JP4590157B2 (ja) 2001-03-21 2010-12-01 アイシス イノヴェイション リミテッド アッセイ、方法および手段
SE0101327D0 (sv) 2001-04-12 2001-04-12 Astrazeneca Ab New crystalline forms
US6566088B1 (en) 2001-10-04 2003-05-20 Board Of Regents, The University Of Texas System Prolyl-4-hydroxylases
GB0124941D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
ES2686625T3 (es) * 2001-12-06 2018-10-18 Fibrogen, Inc. Métodos para el tratamiento o prevención de la anemia
WO2003097040A1 (en) 2002-05-17 2003-11-27 Celgene Corporation Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases
US7157100B2 (en) * 2002-06-04 2007-01-02 J.B. Chemicals & Pharmaceuticals Ltd. Pharmaceutical composition for controlled drug delivery system
AU2003265674B2 (en) 2002-08-29 2008-12-11 Merck & Co., Inc. N-biarylmethyl aminocycloalkanecarboxamide derivatives
EP1554394B1 (en) 2002-10-16 2009-12-16 Isis Innovation Limited Screening methods using a structural model of FIH
CA2506799A1 (en) 2002-11-21 2004-06-10 Eli Lilly And Company Mixed lineage kinase modulators
US8124582B2 (en) 2002-12-06 2012-02-28 Fibrogen, Inc. Treatment of diabetes
US7618940B2 (en) 2002-12-06 2009-11-17 Fibrogen, Inc. Fat regulation
US7183287B2 (en) 2003-04-03 2007-02-27 Pharmacia Corporation Substituted pyrimidinones
US20060251638A1 (en) 2003-06-06 2006-11-09 Volkmar Guenzler-Pukall Cytoprotection through the use of hif hydroxylase inhibitors
US8614204B2 (en) * 2003-06-06 2013-12-24 Fibrogen, Inc. Enhanced erythropoiesis and iron metabolism
KR100932169B1 (ko) 2003-06-06 2009-12-16 피브로겐, 인크. 질소-함유 헤테로아릴 화합물 및 내인성 적혈구생성소의증가에서의 그들의 사용
GB0314129D0 (en) 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
ES2332798T3 (es) 2004-05-28 2010-02-12 Fibrogen, Inc. Ensayo de actividad de la prolil hidroxilasa de hif.
EP1771418A2 (en) 2004-05-31 2007-04-11 Tanabe Seiyaku Co., Ltd. Large conductance calcium-activated k channel opener
CA2573185A1 (en) 2004-07-14 2006-02-23 Ptc Therapeutics, Inc. Methods for treating hepatitis c
TW200616969A (en) 2004-09-17 2006-06-01 Tanabe Seiyaku Co Imidazole compound
US20080213404A1 (en) 2005-02-04 2008-09-04 Johnson Randall S Hif Modulating Compounds and Methods of Use Thereof
DE102005019712A1 (de) 2005-04-28 2006-11-09 Bayer Healthcare Ag Dipyridyl-dihydropyrazolone und ihre Verwendung
CN101849943A (zh) 2005-06-06 2010-10-06 菲布罗根公司 使用HIFα稳定剂的改进的贫血治疗
EP1919463B9 (en) 2005-06-15 2011-02-02 Fibrogen, Inc. Use of hif 1alfa modulators for treatment of cancer
DK1928409T3 (da) 2005-09-12 2012-11-05 Actelion Pharmaceuticals Ltd Stabil farmaceutisk sammensætning omfattende pyrimidin-sulfamid
WO2007033216A2 (en) 2005-09-12 2007-03-22 Beth Israel Deaconess Medical Center Methods and compositions for the treatment and diagnosis of diseases characterized by vascular leak, hypotension, or a procoagulant state
WO2007038571A2 (en) 2005-09-26 2007-04-05 Smithkline Beecham Corporation Prolyl hydroxylase antagonists
US20090176726A1 (en) 2005-10-11 2009-07-09 Fisher David E Methods for treating mitf-related disorders
US7728130B2 (en) 2005-12-09 2010-06-01 Amgen Inc. Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity
GB2453819A (en) 2006-01-09 2009-04-22 Btg Int Ltd Modulators of hypoxia inducible factor-1 and related uses
WO2007082899A1 (en) 2006-01-17 2007-07-26 Vib Vzw Inhibitors of prolyl-hydroxylase 1 for the treatment of skeletal muscle degeneration
JP4801451B2 (ja) 2006-01-19 2011-10-26 株式会社日立ハイテクノロジーズ 走査電子顕微鏡等に用いる電子銃の制御装置及び制御方法
TW200738709A (en) 2006-01-19 2007-10-16 Osi Pharm Inc Fused heterobicyclic kinase inhibitors
ITMI20060179A1 (it) 2006-02-02 2007-08-03 Abiogen Pharma Spa Procedimento per la risoluzione di miscele racemiche e complesso diastereoisomerico di un agente risolvente e di unantiomero di interesse
US7625927B2 (en) 2006-02-27 2009-12-01 Alcon Research, Ltd. Method of treating glaucoma
AR059733A1 (es) 2006-03-07 2008-04-23 Smithkline Beecham Corp Compuesto derivado de glicina n- sustituida con heteroaromaticos bicicicos, composicion farmaceutica que lo comprende, uso para preparar un medicamento para tratar la anemia y proceso para su preparacion
US7588924B2 (en) 2006-03-07 2009-09-15 Procter & Gamble Company Crystal of hypoxia inducible factor 1 alpha prolyl hydroxylase
US20090176825A1 (en) 2006-05-16 2009-07-09 Fitch Duke M Prolyl hydroxylase inhibitors
KR100798730B1 (ko) * 2006-06-12 2008-01-29 신풍제약주식회사 록소프로펜 또는 잘토프로펜 함유 제어방출성 제제 및 그의제조방법
AR061570A1 (es) 2006-06-23 2008-09-03 Smithkline Beecham Corp Compuesto de glicina sustituido en el n heteroaromatico composicion farmaceutica que lo comprende, su uso para preparar un medicamento, procedimientos para preparar dicha composicion farmaceutica y para preparar el compuesto
MX2009000286A (es) * 2006-06-26 2009-03-20 Procter & Gamble Inhibidores de prolil hidroxilasa y metodos de uso.
CA2563690C (en) 2006-10-12 2014-10-07 Pharmascience Inc. Pharmaceutical compositions comprising intra- and extra- granular fractions
IES20070122A2 (en) 2006-12-05 2008-05-28 Michael Hilary Burke A process for the preparation of an orally administered unit dose tablet
CL2008000066A1 (es) 2007-01-12 2008-08-01 Smithkline Beecham Corp Compuestos derivados de (5-hidroxi-3-oxo-2,3-dihidropiridazina-4-carbonil)glicina, inhibidores de hif prolil hidroxilasas; procedimiento de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de la anem
TW200845994A (en) 2007-01-12 2008-12-01 Smithkline Beecham Corp N-substituted glycine derivatives: prolyl hydroxylase inhibitors
EP2134326B1 (en) 2007-04-17 2011-11-16 Ratiopharm GmbH Pharmaceutical compositions comprising irbesartan
CN101663037A (zh) 2007-04-18 2010-03-03 默克公司 新的1,8-二氮杂萘化合物
ES2446418T3 (es) 2007-04-18 2014-03-07 Amgen, Inc Derivados de indanona que inhiben la prolil hidroxilasa
ES2389063T3 (es) 2007-05-04 2012-10-22 Amgen, Inc Derivados de tienopiridina y tiazolopiridina que inhiben la actividad prolil hidroxilasa
WO2008144266A1 (en) 2007-05-16 2008-11-27 Merck & Co., Inc. Spiroindalones
RU2009146851A (ru) 2007-05-18 2011-06-27 Байер Шеринг Фарма Акциенгезельшафт (DE) Гетероарил-замещенные пиразольные производные, которые могут использоваться для лечения гиперпролиферативных нарушений и заболеваний, связанных с ангиогенезом
EP2186528B1 (en) 2007-08-06 2014-03-19 Senju Pharmaceutical Co., Ltd. Pharmaceutical containing hif-1 alpha and hif-2 alpha expression inhibitor
TW200908984A (en) 2007-08-07 2009-03-01 Piramal Life Sciences Ltd Pyridyl derivatives, their preparation and use
CN101815718A (zh) 2007-08-10 2010-08-25 克里斯捷诺米有限公司 吡啶衍生物及其用法
WO2009035534A2 (en) 2007-09-07 2009-03-19 The Cleveland Clinic Foundation Treatment of ischemic eye disease by the systematic pharmaceutical activation of hypoxia inducible factor (hif)
WO2009039321A1 (en) 2007-09-19 2009-03-26 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
WO2009039323A1 (en) 2007-09-19 2009-03-26 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
WO2009043093A1 (en) 2007-10-04 2009-04-09 Newsouth Innovations Pty Limited Hif inhibition
WO2009049112A1 (en) 2007-10-10 2009-04-16 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
WO2009067790A1 (en) 2007-11-26 2009-06-04 Uti Limited Partnership STIMULATION OF HYPOXIA INDUCIBLE FACTOR -1 ALPHA (HIF-1α) FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE ASSOCIATED DISEASE (CDAD), FOR INTESTINAL MOTILITY AND FOR DETECTING INFECTION
EA201000920A1 (ru) 2007-11-30 2011-02-28 ГЛЭКСОСМИТКЛАЙН ЭлЭлСи Ингибиторы пролилгидроксилазы
AU2008331480A1 (en) 2007-11-30 2009-06-11 Glaxosmithkline Llc Prolyl hydroxylase inhibitors
US8269008B2 (en) 2007-12-03 2012-09-18 Fibrogen, Inc. Oxazolopyridine and isoxazolopyridine derivatives for use in the treatment of HIF-mediated conditions
US20100298324A1 (en) 2007-12-19 2010-11-25 Smith Kline Beecham Corporation Prolyl Hydroxylase Inhibitors
WO2009086592A1 (en) 2008-01-04 2009-07-16 Garvan Institute Of Medical Research Method of increasing metabolism
US8952160B2 (en) 2008-01-11 2015-02-10 Fibrogen, Inc. Isothiazole-pyridine derivatives as modulators of HIF (hypoxia inducible factor) activity
JP5380465B2 (ja) 2008-03-03 2014-01-08 アイアールエム・リミテッド・ライアビリティ・カンパニー Ｔｌｒ活性モジュレーターとしての化合物および組成物
WO2010010017A1 (en) 2008-07-23 2010-01-28 F. Hoffmann-La Roche Ag Heterocyclic antiviral compounds
TW201006473A (en) 2008-08-13 2010-02-16 Orient Pharma Co Ltd Bi-layer medicine tablet containing Zaleplon
NZ591394A (en) 2008-09-15 2013-03-28 Kasina Laila Innova Pharmaceuticals Private Ltd Anti-cancer drugs and uses relating thereto for metastatic malignant melanoma and other cancers
HU230877B1 (hu) * 2008-09-30 2018-11-29 EGIS Gyógyszergyár NyR Stabil kombinációs gyógyszerkészítmény
AU2009314155B2 (en) 2008-11-14 2015-10-08 Fibrogen, Inc. Thiochromene derivatives as HIF hydroxylase inhibitors
US8137666B2 (en) * 2008-11-22 2012-03-20 Academia Sinica Nattokinase for degrading and reducing amyloid fibrils—associated with alzheimer's disease, prion diseases and other amyloidoses
ES2811342T3 (es) 2009-03-31 2021-03-11 Ligand Pharm Inc Antagonista de receptores de endotelina y angiotensina II de bifenilsulfonamida para tratar glomeruloesclerosis y nefropatía inducida por IgA
HRP20130846T1 (hr) 2009-03-31 2013-11-22 Kissei Pharmaceutical Co., Ltd. Derivati indolizina i njihova uporaba u medicinske svrhe
PE20120629A1 (es) 2009-07-17 2012-05-30 Japan Tobacco Inc Compuesto triazolopiridina y su accion como inhibidor de prolil hidroxilasa e inductor de la produccion de eritropoyetina
PL2496236T4 (pl) 2009-11-06 2015-11-30 Aerpio Therapeutics Inc Inhibitory hydroksylazy prolilowej
CN103429239A (zh) 2011-01-13 2013-12-04 菲布罗根有限公司 增加网织红细胞血红蛋白含量的方法
CA2837560C (en) 2011-06-06 2017-02-14 Akebia Therapeutics Inc. Compounds and compositions for stabilizing hypoxia inducible factor-2 alpha as a method for treating cancer
NO2686520T3 (cg-RX-API-DMAC7.html) 2011-06-06 2018-03-17
US20130022974A1 (en) 2011-06-17 2013-01-24 The Regents Of The University Of Michigan Dna methylation profiles in cancer
US9206134B2 (en) 2011-07-22 2015-12-08 Beijing Betta Pharmaceuticals Co. Ltd. Polymorphic forms of compounds as prolyl hydroxylase inhibitor, and uses thereof
JP2016519684A (ja) 2013-04-08 2016-07-07 デニス エム ブラウン 準最適に投与された薬物療法の有効性を改善するための及び／又は副作用を低減するための方法および組成物
PT3007695T (pt) 2013-06-13 2024-03-07 Akebia Therapeutics Inc Composições e métodos para tratamento de anemia
RU2016109125A (ru) 2013-08-16 2017-09-22 Огайо Стейт Инновейшн Фаундейшн Композиции и способы модуляции метилирования днк
AR099354A1 (es) 2013-11-15 2016-07-20 Akebia Therapeutics Inc Formas sólidas de ácido {[5-(3-clorofenil)-3-hidroxipiridin-2-carbonil]amino}acético, composiciones, y sus usos
WO2015112831A1 (en) 2014-01-23 2015-07-30 Akebia Therapeutics, Inc. Compositions and methods for treating ocular diseases
CN107427503A (zh) 2015-01-23 2017-12-01 阿克比治疗有限公司 2‑(5‑(3‑氟苯基)‑3‑羟基吡啶甲酰胺)乙酸的固体形式、其组合物及用途
WO2016153996A1 (en) 2015-03-20 2016-09-29 Akebia Therapeutics, Inc. Deuterium-enriched hypoxia-inducible factor prolyl hydroxylase enzyme inhibitors
CR20170450A (es) 2015-04-01 2018-04-03 Akebia Therapeutics Inc Composiciones y métodos para el tratamiento de la anemia
WO2019028150A1 (en) 2017-08-01 2019-02-07 Akebia Therapeutics, Inc. COMPOSITIONS FOR USE IN METHODS OF TREATING HEMOGLOBINOPATHIES
KR20210100594A (ko) 2018-10-03 2021-08-17 아케비아 테라퓨틱스 인코포레이티드 염증성 장애의 치료에 사용하기 위한 벤조이미다졸 유도체
US11524939B2 (en) * 2019-11-13 2022-12-13 Akebia Therapeutics, Inc. Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid

Also Published As

Publication number Publication date
AU2014278543B2 (en) 2019-11-14
CA2914662A1 (en) 2014-12-18
FIC20240023I1 (fi) 2024-06-25
RU2016100363A3 (cg-RX-API-DMAC7.html) 2018-05-15
RU2705206C2 (ru) 2019-11-06
CN114404414A (zh) 2022-04-29
JP2023145717A (ja) 2023-10-11
EP4360706A2 (en) 2024-05-01
PL3007695T3 (pl) 2024-07-01
JP2025114609A (ja) 2025-08-05
KR20210043760A (ko) 2021-04-21
DK3007695T3 (da) 2024-03-18
SI3007695T1 (sl) 2024-04-30
NZ714963A (en) 2020-07-31
MX2015017229A (es) 2016-04-19
RS65341B1 (sr) 2024-04-30
FR24C1025I1 (fr) 2024-07-26
WO2014200773A2 (en) 2014-12-18
IL281058B2 (en) 2023-08-01
FR24C1025I2 (fr) 2025-06-20
RU2019134558A (ru) 2020-02-20
JP2019163293A (ja) 2019-09-26
CN114404413A (zh) 2022-04-29
TWI712411B (zh) 2020-12-11
MX2022003510A (es) 2022-05-16
DOP2015000297A (es) 2016-03-15
KR102373245B1 (ko) 2022-03-17
KR20160023773A (ko) 2016-03-03
TW201534302A (zh) 2015-09-16
AU2014278543A1 (en) 2016-01-07
SMT202400092T1 (it) 2024-05-14
EP4360706A3 (en) 2024-07-10
IL243047B (en) 2019-11-28
NO2024025I1 (no) 2024-05-29
MX2020006963A (es) 2022-03-30
WO2014200773A3 (en) 2015-03-05
KR20220151008A (ko) 2022-11-11
TW202339743A (zh) 2023-10-16
CL2015003602A1 (es) 2016-07-29
KR20240055172A (ko) 2024-04-26
NZ753904A (en) 2020-07-31
AU2020200903B2 (en) 2021-11-04
MX391198B (es) 2025-03-21
TW201922244A (zh) 2019-06-16
IL281058A (en) 2021-04-29
KR102660040B1 (ko) 2024-04-24
TWI650126B (zh) 2019-02-11
HRP20240319T1 (hr) 2024-05-24
CY2024016I2 (el) 2025-05-09
JP2021191773A (ja) 2021-12-16
PT3007695T (pt) 2024-03-07
PH12015502738A1 (en) 2016-03-07
NZ753905A (en) 2020-07-31
CY1126699T1 (el) 2025-05-09
RU2016100363A (ru) 2017-07-18
ZA201509024B (en) 2019-05-29
CY2024016I1 (el) 2025-05-09
SG11201509998WA (en) 2016-01-28
MX378150B (es) 2025-03-10
ES2974273T3 (es) 2024-06-26
TW202133843A (zh) 2021-09-16
LTPA2024521I1 (cg-RX-API-DMAC7.html) 2024-07-10
BR112015031027A2 (pt) 2017-08-29
FI3007695T3 (fi) 2024-03-13
EP3007695A4 (en) 2017-05-31
CA2914662C (en) 2022-05-31
ECSP20058592A (es) 2020-10-30
IL270335B (en) 2021-03-25
AU2020200903A1 (en) 2020-02-27
EP3007695A2 (en) 2016-04-20
AU2022200570B2 (en) 2024-05-02
JP7328291B2 (ja) 2023-08-16
PH12020551705A1 (en) 2021-11-15
TWI856464B (zh) 2024-09-21
NL301278I2 (nl) 2024-08-01
CL2018002372A1 (es) 2018-12-28
JP7672455B2 (ja) 2025-05-07
PE20201496A1 (es) 2020-12-29
JP2020033369A (ja) 2020-03-05
US20240335434A1 (en) 2024-10-10
MY204336A (en) 2024-08-23
AU2024205219A1 (en) 2024-09-19
JP6612479B2 (ja) 2019-11-27
US20160143891A1 (en) 2016-05-26
EP3007695B1 (en) 2024-02-07
CA3151685A1 (en) 2014-12-18
JP2016521747A (ja) 2016-07-25
HK1216844A1 (en) 2016-12-09
HUE066123T2 (hu) 2024-07-28
HUS2400023I1 (hu) 2024-07-28
AU2022200570A1 (en) 2022-02-17
PH12015502738B1 (en) 2021-12-10
JP6937812B2 (ja) 2021-09-22
KR102461176B1 (ko) 2022-11-01
TW202446394A (zh) 2024-12-01
TWI791177B (zh) 2023-02-01
CN105451739A (zh) 2016-03-30
IL281058B1 (en) 2023-04-01
LT3007695T (lt) 2024-03-25
SG10201910773VA (en) 2020-01-30
US11857543B2 (en) 2024-01-02

Similar Documents

Publication Publication Date Title
PE20160194A1 (es) Composiciones y metodos para tratar anemia
AR085668A1 (es) Terapias combinadas para malignidades hematologicas
EA201590450A1 (ru) Сульфамоил-ариламиды и их применение в качестве лекарственных препаратов для лечения гепатита b
EA201590453A1 (ru) Конденсированные бициклические производные сульфамоила и их применение в качестве лекарственных препаратов для лечения гепатита b
UY35243A (es) Inhibidores de fosfatidilinositol 3-cinasa
EA201690223A1 (ru) Ингибиторы фактора в комплемента на основе производных пиперидинилиндола и их применение
BR112019003504A2 (pt) compostos de amino-pirrolopirimidinona e métodos de uso dos mesmos
AR087107A1 (es) Compuesto inhibidor de la señalizacion de la trayectoria notch
EA201690989A1 (ru) Ингибиторы syk
EA201691803A1 (ru) Ингибиторы калликреина плазмы человека
EA201592256A1 (ru) Производные имидазопирролидинона и их применение при лечении заболеваний
MX2017006832A (es) Derivados de ácido biliar como agonistas de fxr/tgr5 y métodos para el uso de los mismos.
GEP201706671B (en) Heterocyclyl compounds as mek inhibitors
PE20142186A1 (es) Derivados biciclicos de pirazinona
EA201491329A1 (ru) 4,4-дизамещенные 1,4-дигидропиримидины и их применение в качестве лекарственных препаратов для лечения гепатита b
NZ715747A (en) Syk inhibitors
EA201490396A1 (ru) Ингибиторы репликации вирусов гриппа
CR20210213A (es) Derivados de quinolina como inhibidores de la integrina alfa4beta7
EA201690277A1 (ru) Производные замещенного глиоксамидом пирроламида и их применение в качестве лекарственных средств для лечения гепатита b
EA201690287A1 (ru) 1,4-дизамещенные аналоги пиридазин хинолина и способы лечения состояний, связанных с smn-дефицитом
EA201592200A1 (ru) Производные сульфамоилпирроламида и их применение в качестве медикаментов для лечения гепатита b
MD20140047A2 (ro) Inhibitori ai protein kinazei
NZ726366A (en) Syk inhibitors
EA201592255A1 (ru) Производные пиразолопирролидин-4-она в качестве ингибиторов вет и их применение при лечении заболевания
ECSP13012658A (es) Composiciones y métodos para el tratamiento de la mielofibrosis